Abstract
Aldosterone, the final component of the renin-angiotensin-aldosterone system, plays an important role in the pathophysiology of hypertension and congestive heart failure. Aldosterone synthase (CYP11B2) catalyzes the last three steps of aldosterone biosynthesis, and as such appears to be a target for the treatment of these disorders. A sulfonamide-imidazole scaffold has proven to be a potent inhibitor of CYP11B2. Furthermore, this scaffold can achieve high levels of selectivity for CYP11B2 over CYP11B1, a key enzyme in the biosynthesis of cortisol.
Copyright 2010 Elsevier Ltd. All rights reserved.
MeSH terms
-
Cytochrome P-450 CYP11B2 / antagonists & inhibitors*
-
Cytochrome P-450 CYP11B2 / metabolism
-
Drug Evaluation, Preclinical
-
Enzyme Inhibitors / chemical synthesis
-
Enzyme Inhibitors / chemistry*
-
Enzyme Inhibitors / pharmacology
-
Imidazoles / chemical synthesis
-
Imidazoles / chemistry
-
Imidazoles / pharmacology
-
Steroid 11-beta-Hydroxylase / antagonists & inhibitors*
-
Steroid 11-beta-Hydroxylase / metabolism
-
Sulfonamides / chemical synthesis
-
Sulfonamides / chemistry
-
Sulfonamides / pharmacology
Substances
-
Enzyme Inhibitors
-
Imidazoles
-
Sulfonamides
-
Cytochrome P-450 CYP11B2
-
Steroid 11-beta-Hydroxylase